constella
abbvie deutschland gmbh & co. kg - linaclotide - irritabel tarm-syndrom - narkotika for forstoppelse - constella er indisert for symptomatisk behandling av moderat til alvorlig irritabel tarmsyndrom med forstoppelse (ibs-c) hos voksne.
gliolan
photonamic gmbh & co. kg - 5-aminolevulinsyre hydroklorid - gliom - antineoplastiske midler - gliolan er indisert hos voksne pasienter for visualisering av ondartet vev under operasjon for ondartet gliom (verdens helseorganisasjon iii og iv).
alacare 8 mg
photonamic gmbh & co. kg - 5-aminolevulinsyre - medisinert plaster - 8 mg
mallozen 3 mg
medice arzneimittel pütter gmbh & co kg - melatonin - tablett - 3 mg
mallozen 2 mg
medice arzneimittel pütter gmbh & co kg - melatonin - tablett - 2 mg
mallozen 5 mg
medice arzneimittel pütter gmbh & co kg - melatonin - tablett - 5 mg
remifemin -
schaper & brümmer gmbh & co kg - klaseormedruerot - tablett
kaletra
abbvie deutschland gmbh co. kg - lopinavir, ritonavir - hiv-infeksjoner - antivirals for systemic use, protease inhibitors - kaletra er angitt i kombinasjon med andre antiretrovirale legemidler til behandling av hiv-1-infiserte voksne, ungdommer og barn i alderen 14 og eldre. valg av kaletra til å behandle protease inhibitor opplevd hiv-1 infiserte pasienter bør være basert på individuelle viral motstand testing og behandling historie av pasienter.
nitrolingual 0.4 mg/ dose
g. pohl-boskamp gmbh & co. - glyseryltrinitrat - sublingvalspray - 0.4 mg/ dose
venclyxto
abbvie deutschland gmbh co. kg - venetoclax - leukemi, lymfocytisk, kronisk, b-celle - antineoplastiske midler - venclyxto in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. venclyxto in combination with rituximab is indicated for the treatment of adult patients with cll who have received at least one prior therapy. venclyxto monotherapy is indicated for the treatment of cll:- in the presence of 17p deletion or tp53 mutation in adult patients who are unsuitable for or have failed a b cell receptor pathway inhibitor, or- in the absence of 17p deletion or tp53 mutation in adult patients who have failed both chemoimmunotherapy and a b-cell receptor pathway inhibitor. venclyxto in combination with a hypomethylating agent is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) who are ineligible for intensive chemotherapy.